Lim M K, Lee C K, Ju Y S, Cho Y S, Lee M S, Yoo B, Moon H B
Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Rheumatol Int. 2001 Apr;20(3):89-93. doi: 10.1007/s002960000083.
To investigate the relationship between serum ferritin and disease activity in systemic lupus erythematosus (SLE), we enrolled 128 patients with SLE (18 males and 110 females). Twenty-eight patients (2 males and 26 females) with rheumatoid arthritis (RA) served as controls. The SLE patients were subdivided into three groups according to Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores: groups A (0-5), B (6-9), and C (> or =10). We prospectively evaluated 48 SLE patients before and after treatment. Serum ferritin and anti-dsDNA antibody were measured by radioimmunometric assay. C-reactive protein (CRP) was measured quantitatively by immunonephelometry. Complements 3 and 4 (C3 and C4) were measured by nephelometry. Serum levels of ferritin during the more active stage of SLE (group C) exceeded those of RA patients and patients at less active stages of SLE (groups A and B). There were no significant differences between RA patients and groups A and B. Serum ferritin was elevated especially in serositis and hematologic manifestation. In this prospective study, changes in SLEDAI scores before and after treatment correlated significantly with serum ferritin levels and inversely to C3 and C4 levels. We confirm that serum ferritin levels can be a useful marker of disease activity in SLE patients.
为了研究系统性红斑狼疮（SLE）患者血清铁蛋白与疾病活动度之间的关系，我们纳入了128例SLE患者（18例男性和110例女性）。28例类风湿关节炎（RA）患者（2例男性和26例女性）作为对照。根据系统性红斑狼疮疾病活动指数（SLEDAI）评分，将SLE患者分为三组：A组（0 - 5分）、B组（6 - 9分）和C组（≥10分）。我们对48例SLE患者治疗前后进行了前瞻性评估。采用放射免疫分析法测定血清铁蛋白和抗双链DNA抗体。采用免疫比浊法定量测定C反应蛋白（CRP）。采用比浊法测定补体3和4（C3和C4）。SLE活动度较高阶段（C组）的血清铁蛋白水平超过RA患者以及SLE活动度较低阶段（A组和B组）的患者。RA患者与A组和B组之间无显著差异。血清铁蛋白升高尤其在浆膜炎和血液学表现中。在这项前瞻性研究中，治疗前后SLEDAI评分的变化与血清铁蛋白水平显著相关，与C3和C4水平呈负相关。我们证实血清铁蛋白水平可作为SLE患者疾病活动度的有用标志物。
